LC
ITOS

Lindbrook Capital’s iTeos Therapeutics ITOS Stock Holding History

Lindbrook Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-172
Closed -$1.32K – 2865
2024
Q4 		$1.32K Sell
172
-12
-7% -$103 ﹤0.01% 2423
2024
Q3 		$1.88K Sell
184
-192
-51% -$2.93K ﹤0.01% 2365
2024
Q2 		$5.58K Buy
376
+94
+33% +$1.35K ﹤0.01% 1947
2024
Q1 		$3.85K Buy
282
+7
+3% +$76 ﹤0.01% 2018
2023
Q4 		$3.01K Buy
275
+31
+13% +$307 ﹤0.01% 2114
2023
Q3 		$2.67K Buy
244
+167
+217% +$2.14K ﹤0.01% 2021
2023
Q2 		$1.02K Buy
77
+53
+221% +$756 ﹤0.01% 2368
2023
Q1 		$327 Sell
24
-52
-68% -$932 ﹤0.01% 2668
2022
Q4 		$1.48K Buy
+76
New +$1.49K ﹤0.01% 2358
2022
Q3 		– Sell
-930
Closed -$21.4K – 2762
2022
Q2 		$19K Hold
930
– – ﹤0.01% 990
2022
Q1 		$30K Hold
930
– – ﹤0.01% 860
2021
Q4 		$43K Buy
+930
New +$31K 0.01% 768
2021
Q3 		– Sell
-1,000
Closed -$26K – 1924
2021
Q2 		$26K Buy
+1,000
New +$23.8K 0.01% 688

Other funds holding ITOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lindbrook Capital's ITOS Position: Q1 2025 in Review

Lindbrook Capital sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 172 shares — an estimated $1.32K sold.

Lindbrook Capital first reported a position in ITOS in Q2 2021 and held it in 13 quarters. The position peaked at $43K in Q4 2021. 132 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Lindbrook Capital reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 172 iTeos Therapeutics shares in Q1 2025, an estimated $1.32K.
  • Lindbrook Capital first reported a position in iTeos Therapeutics in Q2 2021 and held it in 13 quarters.
  • Lindbrook Capital's iTeos Therapeutics position peaked at $43K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.